Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-STROKE asundexian stroke prevention study
NL-OMON59298Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing Asundexian plus background antiplatelet therapy with Placebo plus background antiplatelet therapy (2 arms). Primary endpoints: Time to first occurrence of ischemic stroke and Time to first occurrence of ISTH major bleeding. Started Feb 2023; status: completed.
02
Drugs
asundexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on NL-OMON59298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59298.